MYRIAD GENETICS INC. - COMMON STOCK

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

15 авг 2023 06:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment

08 авг 2023 15:05:01 Источник Nasdaq GlobeNewswire

Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

07 авг 2023 15:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

03 авг 2023 15:05:01 Источник Nasdaq GlobeNewswire

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

27 июл 2023 15:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

06 июл 2023 07:30:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

12 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

07 июн 2023 15:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

01 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

31 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

24 май 2023 15:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Earns 2023 Great Place to Work Certification™

08 май 2023 15:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

03 май 2023 15:05:01 Источник Nasdaq GlobeNewswire

Myriad Genetics to Participate in BofA Securities Healthcare Conference

02 май 2023 15:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

26 апр 2023 15:05:00 Источник Nasdaq GlobeNewswire

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

19 апр 2023 06:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

18 апр 2023 07:00:01 Источник Nasdaq GlobeNewswire

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

02 мар 2023 08:15:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

01 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

28 фев 2023 15:05:01 Источник Nasdaq GlobeNewswire